News

inSPIRE Study

Thu, 07 Nov 2024 16:54:16 GMT

Surveillance Platform for Acute Illness: Respiratory and Enteric Pathogens (inSPIRE)

Respiratory illnesses (for example: ‘a cold’ or ‘the flu’) and gastrointestinal (GI) illnesses (for example: ‘the stomach flu’ or ‘diarrhea’) are some of the most common reasons for people to need medical care. These illnesses can be caused by many different germs including viruses, bacteria, and parasites. The goal of this research study is to find out how often different germs cause respiratory and GI illnesses. We also want to find out about the symptoms and severity of these illnesses.

Over the next 2 years, we will be inviting people to take part in the study when they receive medical care for respiratory or GI illnesses from Marshfield Clinic Health System clinics, emergency departments, and hospitals. Study participants will complete surveys and have nose and throat swabs collected (for a respiratory illness) or give a stool sample (for a GI illness). Samples will be tested to identify the germs that may be causing the illnesses. The study results may help develop better ways to prevent and treat respiratory and GI illnesses.

This study is being led by Joshua Petrie, PhD, MPH, and Huong Nguyen, PhD, MPH at the Marshfield Clinic Research Institute.

inSPIRE Activity Report

Thu, 17 Oct 2024 13:58:15 GMT

Summary

Enrollment update text

Connect for Cancer Prevention Study

Mon, 15 Nov 2021 17:36:04 GMT

The Connect for Cancer Prevention Study wants to better understand the causes of cancer and how to prevent it. Marshfield Clinic Health System is one of nine health care systems throughout the country to partner with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), for Connect. The study will include 200,000 adults who:

Get their health care from a partner health care system,
Are between 40 and 65 years old at enrollment, and
Have never had cancer. People who have or once had non-melanoma skin cancer, or a condition that raises the risk of getting cancer (such as DCIS, or stage 0 breast cancer), can still join.

Participants will be asked to answer online health surveys, donate samples of blood, urine, and saliva, and share access to their electronic health records. This information will help researchers study the health and behavior patterns that may affect cancer risk. It takes time to understand the causes of cancer, so Connect will go on for many years. The longer you participate, the more we may learn.

Learn more about Connect

Find Connect on clinicaltrials.gov

Participants Needed for a Community Research Study

Thu, 17 Sep 2020 16:23:51 GMT

Join Now

The COVID-19 pandemic has affected people in all parts of the country, including the Midwest. There are still many questions about this disease and how it affects people who live in rural areas. The Marshfield Clinic Prospective Assessment of COVID-19 in a Community (PACC) Study is a large research study that will enroll up to 1,500 people of all ages who live in the Marshfield area. The goals are to understand how many people will get infected, how people get infected, and what type of illness people will have in different age groups. Researchers will test nose samples for the virus and blood samples to learn about the immune response to the virus. The study results will help develop more effective ways to prevent and manage COVID-19 in rural communities.

This study is being led by Huong McLean, Ph.D., M.P.H., and Edward Belongia, M.D., at the Marshfield Clinic Research Institute and funded by the U.S. Centers for Disease Control and Prevention (CDC).

What Will Happen in the Study?

If you join the study, you will:

Answer a few questions every week for 52 weeks.
On request, collect and mail in a sample from inside the front of your nose. Some volunteers will collect a nose sample only when they get sick. Others will collect a nose sample every week for 26 weeks in a row.
Come to Marshfield Medical Center in Marshfield for at least 3 blood draws. If you get COVID-19, we may ask you for 2 more blood draws.
Be paid for your time and effort on the study.

You will not receive any treatments or vaccines as part of this study. If a COVID-19 vaccine becomes available to the public during this study, we may request some additional samples or information from people who choose to get vaccinated.

Who Can Join the Study?

At this time, only people who receive an invitation can join the study. Children and adults who live in or around the Marshfield area will be selected randomly (by chance) to be part of this study.

This study is voluntary. You do not have to participate.

If you received an invitation and study code, please fill out the forms on this site to let us know you are interested and confirm that you are eligible. You can contact the study team by phone at 800-468-9700 or email if you have questions.

Join Now

PACC Study Frequently Asked Questions

Thu, 17 Sep 2020 16:29:29 GMT

Why was I selected?
You were randomly selected (like drawing numbers from a hat) because you live in or near Marshfield, Wisconsin.

Why should I join?
COVID-19 is a new disease. There are still many unanswered questions. With your help, we will learn more about COVID-19 in all ages and in rural communities.

Can I volunteer if I did not get an invitation letter?
At this time, we are only allowing people who were selected to participate. However, we may open the study to any volunteers in the future.

Can I volunteer if I don’t have COVID-19?
Yes, you do not have to have COVID-19 to participate in this study.

Is my participation voluntary?
Yes. You should agree to be in the study without feeling pressured. You can decide not to be in the study at any time and that decision will be respected.

Will it hurt when I collect the sample from my nose?
You will collect a sample from inside the front of your nose. We will teach you how to collect the sample. The process is painless and only takes a few minutes. The nose sample we are asking you to collect is different from the sample you would provide if you went to your doctor for a COVID-19 or influenza test. Your doctor will collect a sample from the back of your nose. We want you to collect a sample from inside the front of your nose.

What is the Health System doing to make sure I am safe when I come for my study visits
Marshfield Clinic Health System puts your safety, health and well-being at the forefront of every decision during the COVID-19 pandemic. To learn more about the steps we are taking to keep you safe.

Learn more about these steps >

Are there any potential benefits to participating?
If you provide a nose sample and it is tested for COVID-19 or influenza, you will get the results of that test. Information from this study will help efforts to prevent further spread of COVID-19 in rural areas.

Will I get paid to be in the study?
You will receive payment for your time to complete specific study activities.

Who is paying for this study?
The U.S. Centers for Disease Control and Prevention (CDC).

Partners

Thu, 13 Aug 2020 15:41:38 GMT

Center for Clinical Epidemiology & Population Health

Our investigators direct dozens of research projects totaling more than $3 million in annual funding and are actively involved in numerous collaborative studies with the following networks:

CDC Influenza Vaccine Effectiveness Network

The U.S. Flu Vaccine Effectiveness (VE) Network is a Centers for Disease Control and Prevention (CDC) funded collaboration to assess the effectiveness of influenza vaccination each season. Patients seeking outpatient care for acute respiratory illness are actively recruited during the flu season, and consenting individuals are tested for influenza using a molecular diagnostic test (PCR). Vaccination status is compared for influenza cases and 'test-negative' controls to estimate vaccine effectiveness. Our Center has been continuously funded by CDC to conduct vaccine effectiveness research since the 2004-05 season. The U.S. Flu VE Network currently includes study sites in Seattle, WA; Temple, TX; Ann Arbor, MI; and Pittsburgh, PA in addition to Marshfield. The U.S. Flu VE Network generates mid-season estimates of influenza vaccine effectiveness that are published in the Morbidity and Mortality Weekly Report (MMWR), and final results are published in peer-reviewed journals. Mid-season vaccine effectiveness results are also presented to the World Health Organization Vaccine Strain Selection Committee in February. Marshfield investigators have led ancillary studies to investigate the effects of repeated vaccination and statin use on vaccine effectiveness and studies of vaccine immune response.

Learn more

CDC Vaccine Safety Datalink

Vaccine Safety Datalink (VSD) is a collaborative project between the CDC and nine research managed care organizations (MCOs) in the U.S. Established in 1990 to conduct post-marketing evaluations of vaccine safety, the VSD conducts high quality research to determine the risk of adverse events after immunization. The Marshfield Clinic Research Institute joined the VSD in 2001, and the VSD team is led by investigators in the Center for Clinical Epidemiology and Population Health. Marshfield Clinic Health System and Security Health Plan play a key role contributing data to the only rural population in the VSD network. Our Center researchers have led and published results of studies to evaluate the safety of several vaccines including rotavirus vaccines, influenza vaccines during pregnancy, varicella (chickenpox) vaccines and the HPV vaccine.

Learn more

FDA Sentinel

Sentinel, sponsored by the U.S. Food and Drug Administration (FDA), is an active national surveillance system to monitor the post-market safety of FDA-regulated medical products. Classified as public health surveillance rather than research, Sentinel relies on pre-existing electronic health care data from collaborating data partner organizations that include integrated health systems, large health insurers, an academic center, and a national hospital network. Sentinel data is kept secured at each institution, but standardized to a common data model to allow for efficient data querying. Sentinel partner institutions provide responses to project data queries as well as scientific and organizational expertise. Our Center has been involved in Sentinel since 2008, addressing important topics including severe liver injury, acute kidney injury, and surveillance methodology, in addition to supporting routine safety surveillance.

Learn more

Health Care Systems Research Network

The Health Care Systems Research Network (HCSRN) brings together the research departments of some of the nation's best and most innovative health care systems. Collectively, the HCSRN represents more than 1,400 scientists and research staff with methodological and content expertise from an array of disciplines including epidemiology, economics, disparities, outcomes and quality assessment, trials, genomics, and more. Center scientists have been conducting studies in collaboration with HCSRN partners since 2006 on a variety of topics, with primary focus on topics in cancer, cardiovascular disease, and medical product safety.

Learn more

University of Wisconsin Institute for Clinical and Translational Research, Community Engagement and Research Core

The goal of the University of Wisconsin Institute for Clinical and Translational Research (ICTR) is to create an environment that transforms research training and research practice into a full continuum from discovery to translation into real-world community practice. The mission is to change the research culture from “silos” to collaborations among ICTR members, the entire university, and ICTR's external partner Marshfield Clinic Health System. Major advancements in clinical and translational research are occurring. The Center is the home of Marshfield Clinic Research Institute's Community Engagement and Research Core, with core staff providing service to ICTR investigators in collaborator matching, research design, study development and support and community engagement for population research. Also, Center investigators have collaborated on research with ICTR partners on topics that include lupus, kidney stones, asthma and other allergies, diabetes, oral health, reducing unnecessary hospitalizations, and health care quality reporting.

Learn more

PCORNet - Greater Plains Collaborative (GPC)

The GPC is one of several Clinical Data Research Networks that are funded by the Patient Centered Outcomes Research Institute (PCORI) as part of their PCORNet initiative. PCORNet aims to transform the national platform for biomedical research into one that engages patient, provider, and health system stakeholders in all phases of research, and one that focuses on research questions that are most relevant to patients and other stakeholders. GPC partners include University of Wisconsin, Medical College of Wisconsin, University of Kansas, University of Minnesota, and other centers in the central part of the U.S. In collaboration with the Marshfield Clinic Research Institute Biomedical Informatics Research Center, the Center has engaged in GPC or PCORNet-wide studies on breast cancer, use of targeted cancer therapies, ALS, obesity, cardiovascular disease prevention and others.

Learn more

Research Areas

Thu, 13 Aug 2020 15:22:06 GMT

Center for Clinical Epidemiology & Population Health

Our scientists lead observational and clinical research studies supported by an electronic medical record, medication and immunization registries, a molecular and diagnostic research laboratory, and integrated clinical and research data systems.

Our research addresses a broad range of health issues including cancer care and outcomes, vaccine safety and effectiveness, viral respiratory infections, obesity, diabetes, cardiovascular diseases, and many others. Research teams include clinician investigators, programmer/analysts, masters-prepared epidemiologists, project managers, research coordinators and interviewers. Funding agencies include the Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), Food and Drug Administration (FDA), Patient-Centered Outcomes Research Institute (PCORI), and industry sponsors.

Marshfield Clinic Research Foundation to cohost 22nd Annual HCSRN Conference

Tue, 09 Feb 2016 18:58:14 GMT

Marshfield Clinic Research Foundation (MCRF) will co-host the annual Health Care Systems Reseearch Network (HCSRN) conference along with Henry Ford Health System Research Centers (HFHS). The three-day conference will be held April 14-16, 2016 at the Hyatt Regency in Atlanta, GA. Robert Greenlee, PhD, MPH at MCRF and Lois Lamerato, PhD at HFHS are the Scientific Co-chairs. MCRF last cohosted the 14th annual meeting in 2008, in Minneapolis, MN.

The 2016 conference theme will be “Advancing Population Health: New Models and The Role of Research.” Visit www.HCSRNmeeting.org for more information about the conference

New Flu Vaccine Research Highlights Variable Protection Against Vaccine Strains

Tue, 05 Apr 2016 18:50:00 GMT

A systematic review of nearly a decade of influenza studies across the globe shows influenza vaccines provided substantial protection against the H1N1 strain that has circulated since the 2009 pandemic, and against type B viruses. The study also found that vaccination generates lower protection against the H3N2 viruses that have been infecting humans since the 1960s.

The findings are based on a report published in The Lancet Infectious Diseases. The analysis, which included studies published from 2007 through early 2015, was conducted by Edward Belongia, MD and colleagues at Marshfield Clinic Research Foundation (MCRF) and the University of Minnesota.

The research team screened 3,368 studies and selected 56 that met strict criteria for assessing vaccine effectiveness against different flu subtypes. Seasonal flu vaccines are updated each year and contain two subtypes of influenza A virus (H3N2 and H1N1) and one or two strains of influenza B.

The study team found that seasonal vaccines provided 61 percent protection against the H1N1 strain and 54 percent protection against type B. Vaccine protection was only 33 percent for the H3N2 strain. Although vaccine effectiveness can decline in older adults due to aging of the immune system, the review found that protection against H1N1 and type B was maintained even in the oldest age groups.

“It’s reassuring to see that flu vaccines around the world consistently provide moderately high protection against two major flu subtypes,” said Belongia, director, MCRF Center for Clinical Epidemiology & Population Health. “This year we are seeing mostly H1N1 and B infections, and mid-season estimates from the U.S. and Canada show substantial vaccine protection as expected based on our systematic review.”

Influenza seasons are unpredictable with circulation of different virus subtypes. Seasons with mostly H3N2 viruses tend to be more severe, and H3N2 evolves more rapidly to evade the immune system compared to other flu viruses.

“The reasons for lower vaccine protection against H3N2 are unclear, but we suspect continuous virus evolution in nature and egg-based vaccine production may be contributing,” Belongia said. When H3N2 vaccine strains are adapted to grow in eggs, mutations can occur that affect the ability of the immune system to target the virus.

The review included studies that measured vaccine effectiveness by comparing vaccination frequency in patients with lab confirmed flu and in control patients who had a similar illness but tested negative for the flu virus. This “test-negative” approach was first used in 2005 and has been widely adopted in several countries. Three quarters of the studies included in the review were conducted in Europe or North America, and over 90 percent were published after 2010.

MCRF has conducted annual studies of influenza vaccine effectiveness for the past 12 years. There was no funding source for this study.

A copy of this paper can be found at http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(16)00129-8/abstract.

Marshfield Clinic Earns Accreditation for Human Subject Research Protection

Thu, 26 Mar 2015 20:11:02 GMT

Marshfield Clinic’s human research protection program has earned national recognition for its commitment to protect research participants.

The Clinic was accredited by the Association for the Accreditation of Human Research Protection Programs, Inc. (AAHRPP), which promotes high-quality research through an accreditation process that helps organizations worldwide strengthen human research protection programs.

This accreditation demonstrates Marshfield Clinic Research Foundation (MCRF) strengthened protections for research participants, which helps build public trust and confidence in research.

AAHRPP accreditation is considered the gold standard for quality research programs. All major U.S. independent institutional review boards (IRB) are AAHRPP accredited. More than 60 percent of U.S. research-intensive universities and 65 percent of U.S. medical schools are either AAHRPP accredited or have begun the accreditation process.

“Accreditation demonstrates our ongoing commitment to human subjects’ protections and quality in research,” said Steve Ziemba, PhD, MCRF associate director. “It also raises our national profile and makes the Clinic a more attractive option for clinical trials and research.”

The process began more than two years ago after the University of Wisconsin and the Medical College of Wisconsin, which partners with MCRF on numerous research projects, received accreditation.

“We saw their programs go through the process and recognized the value they received,” said Linda Jaros, Clinic research compliance officer. “We knew our program was of high quality and a candidate for accreditation so we committed to the process.”

MCRF conducted a thorough review of policies and procedures and submitted more than 500 pages that detailed quality measures and other requirements. An AAHRPP site visit last fall further documented the Clinic’s commitment to quality improvement.

Lori Scheller, MCRF IRB administrator, said federal regulation guidelines are considered a baseline for compliance. Accreditation has a higher level of compliance.

“Sponsors for medical device manufacturers and pharmaceutical companies look for an organization or research program doing human research trials above and beyond federal regulations,” Scheller said. “This gives us a competitive advantage when pharmaceutical sponsors are looking for trial sites. They know we run quality research programs.”

Some of the Clinic’s research collaborations require data and specimen sharing among accredited institutions. This ensures privacy, data protection, and bio-banking meet high standards and demonstrates a built-in trust between institutions.

test page cceph

Tue, 04 Aug 2015 14:45:37 GMT

Test superscript Justin^Knecht will this work superscript.

Test subscript Justin_Knecht will this work subscript.

test_²

subpar²

Delta Dental awards $170,000 for dental sealant registry

Fri, 19 Jun 2015 18:42:18 GMT

Delta Dental of Wisconsin has awarded $170,000 to the Institute for Oral and Systemic Health (IOSH), a division of Marshfield Clinic Research Foundation (MCRF), to expand its research and development of DentaSeal.

DentaSeal is a secure, web-based dental sealant registry software program developed by the DentaSeal project team at MCRF. The project team worked with Children’s Health Alliance of Wisconsin and the Wisconsin Department of Health Services (DHS) to understand business needs of school-based sealant programs. Delta Dental of Wisconsin has supported DentaSeal since its inception.

“Delta Dental of Wisconsin has a longstanding collaborative relationship with Marshfield Clinic and has been working with IOSH on key research and development projects,” said Narayana Murali, M.D., Marshfield Clinic executive director. “Delta Dental’s contribution to supporting school-based sealant programs (SBSP) and necessary health information technology tools is a true testament to their public health mission and commitment to serving communities in our state.”

More than 40 percent of children have tooth decay by kindergarten and the prevalence of tooth decay in poor children under the age of 5 is increasing, according to the American Academy of Pediatric Dentistry.

Dental sealant application is considered an evidence-based, preventive strategy for children and is commonly used in private practice dentistry. SBSPs increase sealant use and reduce tooth decay by targeting schools serving children from low-income families and focus on sealing newly erupted permanent molars.

DentaSeal can be used to:

Capture, evaluate and track effectiveness and efficiency of SBSPs across multiple years.
Serve as an intuitive data capture tool that provides users the ability to accurately collect/look up a child’s oral health/dental sealant information.
Be a real-time reporting tool that queries useful information during the school year and for end-of-year reports.

“DentaSeal is revolutionizing the way school-based sealant data is collected and keeps Wisconsin at the forefront in this arena,” said Matt Crespin, associate director, Children’s Health Alliance of Wisconsin. “The ability to more accurately collect timely data is a critical area that DentaSeal addresses. Programs statewide have welcomed and embraced this change.”

Wisconsin’s Seal-A-Smile sealant program, with support from Delta Dental, is a nationally recognized model for SBSPs’ implementation and success. Children’s Health Alliance leads and manages the Seal-A-Smile program in collaboration with DHS’ Oral Health Program.

DentaSeal was used extensively within Wisconsin’s 40 Seal-A-Smile programs and supported approximately 50,000 children’s dental sealant records during the 2014-15 school year in Wisconsin. An enhanced, stable version of DentaSeal with unique features like dashboard capabilities, enhanced tooth charting features, fiscal management and reporting services is being developed for the 2015-16 school year.

“The ability of our software to track dental sealant treatment outcome across multiple years for children in Wisconsin’s SBSP makes it powerful,” said Amit Acharya, B.D.S., Ph.D., IOSH director and DentaSeal project director. “We look forward to collaborating with other states to disseminate our product in the future.”

Besides Dr. Acharya, DentaSeal project team members are Joe Ellefson, technical advisor; Annie Steinmetz, project manager; Will Ray, application architect and lead developer; Dixie Schroeder, project coordinator; Kate Baker, usability analyst; Ryan Frahm, systems administrator; Shawn Halstead, database administrator; and Harshad Hegde, programmer analyst. This team collaborates with Delta Dental, Children's Health Alliance of Wisconsin and DHS to further refine software.

“The grant for DentaSeal embodies all components of Delta Dental’s mission – to improve oral health by extending access to care, advancing science and supporting an effective oral health workforce,” said Dennis Brown, Delta Dental CEO. “By developing improved data tools, we can help advance science and support the dental workforce that provides care at school-based programs.”

Study: New approach helps ID possible novel uses for existing drugs

Tue, 21 Apr 2015 20:37:25 GMT

Finding new uses for existing drugs has become increasingly important for treating diseases. A Marshfield Clinic-led research team has proven a new way to speed up the process, according to a study published Wednesday, April 8, in Nature Biotechnology.

Drug repurposing is the process of discovering new uses for existing drugs. The process is becoming increasingly important in drug development as success rates for new drugs in clinical trials decrease and costs increase. Initially identifying candidate drug-disease relationships is critical to drug repurposing.

Using a type of genetic study called a phenome-wide association study, researchers identified thousands of potential disease and drug relationships. This could serve as an early clue when looking for drugs that may effectively treat diseases they are not currently prescribed for.

“This is a proof of principle study demonstrating phenome-wide association data may be rapidly applied to developing or repurposing existing drugs,” said Scott Hebbring, Ph.D., principal investigator and research scientist, Marshfield Clinic Research Foundation’s Center for Human Genetics. “Unlike other genetic-based approaches, a phenome-wide association study allows us to look at thousands of diseases at once, rather than just one disease at a time.”

A team of researchers, using the phenome-wide approach, identified more than 14,800 examples of where a drug might be used to treat an unrelated disease. They did this by cross-referencing drug-disease pairs identified by phenome-wide data with existing medical literature to find examples where a disease and drug were mentioned in the same article.

“While we didn’t provide context for these relationships, we hope these novel findings offer researchers clues that allow them to prioritize which potential relationships to study first,” Hebbring said. “That, in turn, could help us more quickly find new uses for current drugs.”

They also found more than 38,000 novel drug-disease relationships not yet studied, according to the medical literature. These results suggest phenome-wide association study data may bring to light many additional diseases that may be treated with already developed drugs.

To read the full study, go to Nature Biotechnology.

NFMC, Migrant Clinicians Network receive research collaboration award from National Safety Council

Fri, 19 Jun 2015 17:26:45 GMT

The National Farm Medicine Center (NFMC), Migrant Clinicians Network (MCN) and four partner organizations received the inaugural Stakeholder Collaboration in Occupational Injury Research Award, sponsored by the National Safety Council (NSC).

The award was presented May 19 as part of the National Occupational Injury Research Symposium (NOIRS) 2015 in Kingwood, West Virginia. The award recognizes broad stakeholder collaborative efforts in the Seguridad en las Lecherías: Immigrant Dairy Worker Health and Safety Project, being conducted in Wisconsin.

Iris Anne Reyes, National Farm Medicine Center (left) and Amy Liebman, Migrant Clinicians Network (middle) accept the Stakeholder Collaboration in Occupational Injury Research Award, presented May 19 by National Safety Council President and CEO Deborah Hersman at the National Occupational Injury Research Symposium 2015 in Kingwood, West Virginia.

“Dairy workers have a high rate of occupational injury,” said Amy Liebman, co-director for the project and director of environmental and occupational health at MCN. “The Seguridad project shows that for a huge problem like work-related health and safety on dairy farms, collaboration between workers, producers, researchers, and health and safety practitioners is an effective approach to ensure worker protection.”

Liebman and NFMC Project Coordinator Iris Anne Reyes accepted the award on behalf of the project team, which is led by NFMC Director Matthew Keifer, M.D., and includes NFMC’s Yurany Ninco Sanchez, community outreach trainer. NFMC is part of Marshfield Clinic Research Foundation (MCRF).

Partner organizations included: Professional Dairy Producers of Wisconsin; the Consulate of Mexico in Saint Paul, Minnesota; the University of Wisconsin-River Falls; and Wisconsin nonprofit Puentes/Bridges.

Agriculture lacks many worker health and safety regulations found in other industries. An increasing number of immigrants with limited experience, unaddressed safety training needs, and language barriers are hired to work in dairy. Few resources are geared for this population and farmers lack the safety, language, and cultural knowledge to train these workers in health and safety.

The Seguridad project tests culturally-appropriate popular education approaches and the promotor de salud, or community health worker model, to provide health and safety training to immigrant dairy workers in Wisconsin. In the promotor model, lay people are trained to educate their peers.

To date, the Seguridad project has partnered with 54 farms throughout Wisconsin, training 737 workers and 37 promotores, totaling over 2,639 training hours. This effort has resulted in a demonstrated increase in health and safety knowledge among participating dairy workers.

“The community health worker model engages workers in helping to solve health and safety issues on the farm and creates an important opportunity for worker-management interaction, while bridging cultural and language barriers,” Dr. Keifer said. “We are testing to see if it has measurable impact on health and safety on dairy farms – and so far, our data suggest that it does.”

The awarding entity, National Safety Council, is a nonprofit organization with the mission to save lives by preventing injuries and deaths.

“Working together gives us the greatest opportunity to save lives and prevent injuries,” said Deborah Hersman, president and CEO of the National Safety Council. “NSC is excited to present the inaugural Stakeholder Collaboration in Occupational Injury Research Award to the National Farm Medicine Center, Migrant Clinicians Network and their partners. Their collaborative efforts to reach a population of workers in dire need of attention set them apart from other nominees.”

The project is supported by the Upper Midwest Agricultural Safety and Health Center (UMASH), a center funded by the National Institute for Occupational Safety and Health.

“We are thrilled for the Farm Center and its partners,” said Robert Steiner, M.D., MCRF executive director. “The type of research being done in the Seguridad project puts the NFMC/UMASH team in close contact with the community they are serving, and is making dairy farms safer places to work.”

2014 Publications

Fri, 05 Jun 2015 18:35:57 GMT

Bartels CM, Buhr KA, Goldberg JW, Bell CL, Visekruna M, Nekkanti S, Greenlee RT. Mortality and cardiovascular burden of systemic lupus erythematosus in a US population-based cohort. J Rheumatol. 2014 Apr;41(4):680-7. PMID: 24532834.

Belongia EA, Sundaram ME, McClure DL, Meece JK, Ferdinands J, VanWormer JJ. Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season. Vaccine. Epub 2014 June 21. PMID: 24962752.

Borne RT, Peterson PN, Greenlee R, Heidenreich PA, Wang Y, Curtis JP, Tzou WS, Varosy PD, Kremers MS, Masoudi FA. Temporal trends in patient characteristics and outcomes among Medicare beneficiaries undergoing primary prevention implantable cardioverter-defibrillator placement in the United States, 2006 – 2010. Results from the National Cardiovascular Data Registry’s Implantable Cardioverter-Defibrillator Registry. Circulation. 2014 Sep; 130(10): 845-53. PMID: 25095884.

Donahue JG, Kieke BA, Szilagy PG, Blumkin AK, Hilgemann D, Flanders WD, Shay DK, Meece J, Gallivan S, Treanor J, Belongia EA. Can the rolling cross-sectional survey design be used to estimate the effectiveness of influenza vaccines? Vaccine. Epub 2014 Oct 3. PMID: 25284810

Dugdale C, Chow BD, Yakirevich E, Kojic E, Knoll B. Prolonged pyrexia and hepatitis: Q fever. Am J Med. 2014 Oct;[Epub ahead of print]. PMID: 24929020

Flannery B, Thaker S, Clippard J, Monto A, Ohmit SE, Zimmerman R, Nowalk M, Gaglani M, Jackson M, Jackson L, Belongia EA, McLean (Nguyen) HQ, Berman L, Foust A, Sessions W, Spencer S, Fry A, Influenza Division, National Center for Immunization and Respiratory Diseases, CDC . Interim estimates of 2013-14 seasonal influenza vaccine effectiveness - United States, February 2014. MMWR Morb Mortal Wkly Rep. 2014;63(7):137-42. PMID: 24553196

Havers F, Thaker S, Clippard JR, Jackson M, McLean HQ, Gaglani M, Monto AS, Zimmerman RK, Jackson L, Petrie JG, Nowalk MP, Moehling KK, Flannery B, Thompson MG, Fry AM. Use of influenza antiviral agents by ambulatory care clinicians during the 2012-2013 influenza season. Clin Infect Dis. 2014 Sep; 59(6): 774-82. PMID: 25034419

Ittaman SV, VanWormer JJ, Rezkalla SH. The role of aspirin in the prevention of cardiovascular disease. Clinical Medicine & Research. Epub 2014 Feb 26. PMID: 24573704

Jackson ML, Peterson D, Nelson JC, Greene SK, Jacobsen SJ, Belongia EA, Baxter R, Jackson LA. Using winter 2009-2010 to assess the accuracy of methods which estimate influenza-related morbidity and mortality. Epidemiol Infect.. 2014;12:1-9. PMID: 25496703

Kieke AL, Kieke BA, Kopitzke SL, McClure DL, Belongia EA, VanWormer JJ, Greenlee RT. Validation of Health Event Capture in the Marshfield Epidemiologic Study Area Clin Med Res. 2014 Dec; [Epub ahead of print]. PMID: 25487238

Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, Rosenberg Y, Eby C, Madigan R, McBane R, Abdel-Rahman S, Stevens S, Yale SH, Mohler E, Fang M, Shah V, Horenstein R, Limdi NA, Muldowney J, Gujral J, Delafontaine P, Desnick RJ, Ortel T, Billett H, Pendleton RC, Geller N, Halperin J, Goldhaber S, Caldwell MD, Califf RM, Ellenberg J, COAG Investigators , Kohnhorst D, Strey SK, Burmester JK, Schmelzer JR, Mazza JJ, Bhupathi S. A pharmacogenetic versus a clinical algorithm for warfarin dosing. NEW ENGL J MED. 2013;369(24):2283-93. PMID: 24251361

Kutty P, McLean (Nguyen) HQ, Lawler J, Schulte C, Hudson J, Blog D, Wallace G. Risk Factors for Transmission of Mumps in a Highly Vaccinated Population in Orange County, New York, 2009-2010. PEDIATR INFECT DIS J. 2014;33(2):121-5. PMID: 23995590

Limbo R, Glasser J, Sundaram ME. "Being Sure": Women's Experience With Inevitable Miscarriage. MCN Am J Matern Child Nurs. 2014;39(3):165-74. PMID: 24472796

McCarty CA, Berg RL, Rottscheit CM, Waudby CJ, Kitchner TE, Brilliant MH. Validation of PhenX measures in the personalized medicine research project for use in gene/environment studies. BMC Med Genomics. 2014;7(1):3. PMID: 24423110

McClure DL, Kieke BA, Sundaram ME, Simpson MD, Meece JK, Frangiscos S, Gasser RA, Belongia EA. Seasonal incidence of medically attended respiratory syncytial virus infection in a community cohort of adults 50 years and older. PLoS One. 2014 July; 9(7). PMID: 25025344.

McClure DL, VanWormer JJ, Waring SC, Elliot T, Bailey-Davis L, Copeland L. D3-1: HMO Research Network Rural Health Scientific Interest Group (Rural Health-SIG): Highlights from Four Member Sites and Opportunities for Collaboration Clin Med Res. 2014 Sept;12(1-2):d3-1. CM&R

McLean HQ, Meece JK, Belongia EA. Influenza vaccination and risk of hospitalization among adults with laboratory confirmed influenza illness . Vaccine. 2014 Jan 16;32(4):453-7. Epub 2013 Nov 26. PMID:24291201

McLean HQ, Thompson MG, Sundaram ME, Meece JK, McClure DL, Friedrich TC, Belongia EA. Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons. Clin Infect Dis. 2014 Nov; 59(10): 1375-85. PMID: 25270645.

McLean, Huong Q., Thompson, Mark G., Sundaram, Maria E., Kieke, Burney A., Gaglani, Manjusha, Murthy, Kempapura, Piedra, Pedro A., Zimmerman, Richard K., Nowalk, Mary Patricia, Raviotta, Jonathan M., Jackson, Michael L., Jackson, Lisa, Ohmit, Suzanne E., Petrie, Joshua G., Monto, Arnold S., Meece, Jennifer K., Thaker, Swathi N., Clippard, Jessie R., Spencer, Sarah M., Fry, Alicia M., Belongia, EA. Influenza Vaccine Effectiveness in the United States During 2012-13: Variable Protection by Age and Virus Type. J INFECT DIS. 2014; [Epub ahead of print]. PMID: 25406334

McNeil, MM, Gee J, Weintraub ES, Belongia EA, Lee GM, Glanz JM, Nordin JD, Klein NP, Baxter R, Naleway AL, Jackson LA, Omer SB, Jacobsen SJ, DeStefano F. The Vaccine Safety Datalink: success and challenges monitoring vaccine safety. Vaccine. 2014 Sep; 32(42) 5390-8. PMID: 25108215.

Osterholm MT, Kelley NS, Belongia EA, Jackson L, Jackson M. Reply: Cochrane rearranged. VACCINE. 2014;Epub Ahead of Print:pii: S0264-410X(14)00160-1. PMID: 24530402

Peissig PL, Santos Costa V, Caldwell MD, Rottscheit CM, Berg RL, Mendonca EA, Page D. Relational machine learning for electronic health record-driven phenotyping. J Biomed Inform. 2014; Epub ahead of print. PMID: 25048351

Ross T, Lin C, Nowalk M, Huang H, Spencer S, Shay DK, Sambhara S, Sundaram ME, Friedrich T, Sauereisen S, Bloom C, Zimmerman R. Influence of pre-existing hemagglutination inhibition titers against historical influenza strains on antibody response to inactivated trivalent influenza vaccine in adults 50-80 years of age. Hum Vaccin Immunother. 2014;10(5): Epub Ahead of Print. PMID: 24614078

Sillah A, Sidebottom A, Boucher JL, Pereira RF, VanWormer JJ. Program participation and blood pressure improvement in the heart of New Ulm Project, Minnesota, 2009-2011. Prev Chronic Dis. 2014;11 PMID: 24674634

Sundaram ME, Meece JK, Sifakis F, Gasser R, Belongia EA. Medically attended respiratory syncytial virus infections in adults aged >=50 years: clinical characteristics and outcomes. CLIN INFECT DIS. 2014;58(3):342-9. PMID: 24265361

Sundaram ME, Meydani SN, Vandermause MF, Shay DK, Coleman LA. Vitamin E, vitamin A, and zinc status are not related to serologic response to influenza vaccine in older adults: an observational prospective cohort study. NUTR RES. 2014;34(2):149-54.

VanWormer JJ, Miller AW, Rezkalla SH. Aspirin overutilization for the primary prevention of cardiovascular disease. Clin Epidemiol.. 2014;6:433-40. PMID: 25506245

VanWormer JJ, Miller AW, Rezkalla SH. PS2-12: Identifying Opportunities to Improve Aspirin Utilization for the Primary Prevention of Cardiovascular Disease in a Regional Healthcare System Clin Med Res. 2014 Oct;12(1-2):Ps2-12. PMID: 25739162

VanWormer JJ, Sundaram ME, Meece JK, Belongia EA. A cross-sectional analysis of symptom severity in adults with influenza and other acute respiratory illness in the outpatient setting. BMC Infectious Diseases. 2014 May;14(231). PMID: 24884932.

Weintraub ES, Baggs J, Duffy J, Vellozzi C, Belongia EA, Irving SA, Klein NP, Glanz JM, Jacobsen SJ, Naleway A, Jackson LA, DeStefano F. Risk of Intussusception after Monovalent Rotavirus Vaccination. NEW ENGL J MED. 2014;370(6):513-9. PMID: 24422678

2013 Publications

Fri, 05 Jun 2015 19:14:40 GMT

Acharya A, VanWormer JJ, Waring SC, Miller AW, Fuehrer JT, Nycz GR. Regional epidemiologic assessment of prevalent periodontitis using an electronic health record system. Am J Epidemiol. 2013 Apr 1;177(7):700-7. Epub 2013 Mar 4. PMID:23462966

Bateman AC, Kieke BA, Irving SA, Meece JK, Shay DK, Belongia EA. Effectiveness of monovalent 2009 pandemic influenza A virus subtype H1N1 and 2010-2011 trivalent inactivated influenza vaccines in Wisconsin during the 2010-2011 influenza season. J Infect Dis. 2013 Apr 15;207(8):1262-9. Epub 2013 Jan 22. PMID:23341536

Benson GA, Sidebottom A, VanWormer JJ, Boucher JL, Stephens C, Krikava J. HeartBeat Connections: A Rural Community of Solution for Cardiovascular Health. J Am Board Fam Med. 2013 May-Jun;26(3):299-310. doi: 10.3122/jabfm.2013.03.120240. PMID:23657698

Catlett AV, Greenlee R. A retrospective comparison of dental hygiene supervision changes from 2001 to 2011. J Dent Hyg. 2013 June; 87(3):110-7. PMID: 23986327

Doubeni CA, Weinmann S, Adams K, Kamineni A, Buist DS, Ash AS, Rutter CM, Doria-Rose VP, Corley DA, Greenlee RT, Chubak J, Williams A, Kroll-Desrosiers AR, Johnson E, Webster J, Richert-Boe K, Levin TR, Fletcher RH, Weiss NS. Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average-risk adults: a nested case-control study. Ann Intern Med. 2013 Mar 5;158(5 Pt 1):312-20. PMID:23460054

Drahos J, Vanwormer JJ, Greenlee RT, Landgren O, Koshiol J. Accuracy of ICD-9-CM codes in identifying infections of pneumonia and herpes simplex virus in administrative data. Ann Epidemiol. 2013 May;23(5):291-3. Epub 2013 Mar 22. PMID:23522903

Ferdinands JM, Gargiullo P, Haber M, Moore M, Belongia EA, Shay DK. Inactivated influenza vaccines for prevention of community-acquired pneumonia: the limits of using nonspecific outcomes in vaccine effectiveness studies. Epidemiology. 2013 Jul;24(4):530-7. PMID:23732734

Glanz JM, Newcomer SR, Narwaney KJ, Hambidge SJ, Daley MF, Wagner NM, McClure DL, Xu S, Rowhani-Rahbar A, Lee GM, Nelson JC, Donahue JG, Naleway AL, Nordin JD, Lugg MM, Weintraub ES. A population-based cohort study of undervaccination in 8 managed care organizations across the United States. JAMA Pediatr. 2013 Mar 1;167(3):274-81. PMID:23338829

Glanz JM, Wagner NM, Narwaney KJ, Shoup JA, McClure DL, McCormick EV, Daley MF. A mixed methods study of parental vaccine decision making and parent-provider trust. Acad Pediatr. 2013 Sep-Oct;13(5):481-8. PMID:24011751

Greene SK, Rett MD, Vellozzi C, Li L, Kulldorff M, Marcy SM, Daley MF, Belongia EA, Baxter R, Fireman BH, Jackson ML, Omer SB, Nordin JD, Jin R, Weintraub ES, Vijayadeva V, Lee GM. Guillain-Barré Syndrome, Influenza Vaccination, and Antecedent Respiratory and Gastrointestinal Infections: A Case-Centered Analysis in the Vaccine Safety Datalink, 2009-2011. PLoS One. 2013 Jun 26;8(6):e67185. Print 2013. PMID:23840621

Hechter RC, Qian L, Sy LS, Greene SK, Weintraub ES, Naleway AL, Rowhani-Rahbar A, Donahue JG, Daley MF, Vazquez-Benitez G, Lugg MM, Jacobsen SJ. Secular trends in diagnostic code density in electronic healthcare data from health care systems in the Vaccine Safety Datalink project. Vaccine. 2013 Feb 4;31(7):1080-5. Epub 2012 Dec 23. PMID:23267842

Henninger M, Naleway A, Crane B, Donahue J, Irving S. Predictors of seasonal influenza vaccination during pregnancy. Obstet Gynecol. 2013 Apr;121(4):741-9. PMID: 23635673

Irving SA, Kieke BA, Donahue JG, Mascola MA, Baggs J, DeStefano F, Cheetham TC, Jackson LA, Naleway AL, Glanz JM, Nordin JD, Belongia EA; Vaccine Safety Datalink. Trivalent inactivated influenza vaccine and spontaneous abortion. Obstet Gynecol. 2013 Jan;121(1):159-65. PMID:23262941

Jackson LA, Peterson D, Nelson JC, Marcy SM, Naleway AL, Nordin JD, Donahue JG, Hambidge SJ, Balsbaugh C, Baxter R, Marsh T, Madziwa L, Weintraub E. Vaccination site and risk of local reactions in children 1 through 6 years of age. Pediatrics. 2013 Feb;131(2):283-9. Epub 2013 Jan 14. PMID:23319538

Jackson ML, Yu O, Nelson JC, Naleway A, Belongia EA, Baxter R, Narwaney K, Jacobsen SJ, Shay DK, Jackson LA. Further evidence for bias in observational studies of influenza vaccine effectiveness: the 2009 influenza A(H1N1) pandemic. Am J Epidemiol. 2013 Oct 15;178(8):1327-36. Epub 2013 Aug 26. PMID: 23978527

Kjos SA, Irving SA, Meece JK, Belongia EA. Elementary school-based influenza vaccination: evaluating impact on respiratory illness absenteeism and laboratory-confirmed influenza. PLoS One. 2013 Aug 26;8(8):e72243. PMID:23991071

Lo Re V 3rd, Haynes K, Goldberg D, Forde KA, Carbonari DM, Leidl KB, Hennessy S, Reddy KR, Pawloski PA, Daniel GW, Cheetham TC, Iyer A, Coughlin KO, Toh S, Boudreau DM, Selvam N, Cooper WO, Selvan MS, VanWormer JJ, Avigan MI, Houstoun M, Zornberg GL, Racoosin JA, Shoaibi A. Validity of diagnostic codes to identify cases of severe acute liver injury in the US Food and Drug Administration's Mini-Sentinel Distributed Database. Pharmacoepidemiol Drug Saf. 2013 Aug;22(8):861-72. Epub 2013 Jun 25. PMID:23801638

Matlock DD, Groeneveld PW, Sidney S, Shetterly S, Goodrich G, Glenn K, Xu S, Yang L, Farmer SA, Reynolds K, Cassidy-Bushrow AE, Lieu T, Boudreau DM, Greenlee RT, Tom J, Vupputuri S, Adams KF, Smith DH, Gunter MJ, Go AS, Magid DJ. Geographic variation in cardiovascular procedure use among Medicare fee-for-service vs Medicare Advantage beneficiaries. JAMA. 2013 Jul 10;310(2):155-62. PMID:23839749

McCarthy NL, Irving S, Donahue JG, Weintraub E, Gee J, Belongia E, Baggs J. Vaccination coverage levels among children enrolled in the Vaccine Safety Datalink. Vaccine. 2013 Dec 2;31(49):5822-6. Epub 2013 Oct 14. PMID:24135576

McCarthy NL, Weintraub E, Vellozzi C, Duffy J, Gee J, Donahue JG, Jackson ML, Lee GM, Glanz J, Baxter R, Lugg MM, Naleway A, Omer SB, Nakasato C, Vazquez-Benitez G, DeStefano F. Mortality rates and cause-of-death patterns in a vaccinated population. Am J Prev Med. 2013 Jul;45(1):91-7. PMID:23790993

Miglioretti DL, Johnson E, Williams A, Greenlee RT, Weinmann S, Solberg LI, Feigelson HS, Roblin D, Flynn MJ, Vanneman N, Smith-Bindman R. The use of computed tomography in pediatrics and the associated radiation exposure and estimated cancer risk. JAMA Pediatr. 2013 Aug 1;167(8):700-7. PMID:23754213

Muñoz-Zanzi C, Williams-Nguyen J, Belongia EA. A sero-survey of toxoplasmosis in farm and non-farm children from Wisconsin, United States, 1997-1999. BMC Public Health. 2013 Sep 11;13:837. PMID:24025220

Newcomer SR, Hambidge SJ, McClure DL, Daley MF, Klein NP, Glanz JM. Factors that may explain observed associations between trivalent influenza vaccination and gastrointestinal illness in young children. Vaccine. 2013 Aug 20;31(37):3894-8. Epub 2013 Jul 2. PMID:23831326

Ohmit SE, Thompson MG, Petrie JG, Thaker SN, Jackson ML, Belongia EA, Zimmerman RK, Gaglani M, Lamerato L, Spencer SM, Jackson L, Meece JK, Nowalk MP, Song J, Zervos M, Cheng PY, Rinaldo CR, Clipper L, Shay DK, Piedra P, Monto AS. Influenza Vaccine Effectiveness in the 2011-2012 Season: Protection Against Each Circulating Virus and the Effect of Prior Vaccination on Estimates. Clin Infect Dis. 2013 Nov 22. [Epub ahead of print] PMID:24235265

Partridge EE, Greenlee RT, Riley TL, Commins J, Ragard L, Xu JL, Buys SS, Prorok PC, Fouad MN. Assessing the risk of ovarian malignancy in asymptomatic women with abnormal CA 125 and transvaginal ultrasound scans in the prostate, lung, colorectal, and ovarian screening trial. Obstet Gynecol. 2013 Jan;121(1):25-31. PMID:23262924

Peterson PN, Varosy PD, Heidenreich PA, Wang Y, Dewland TA, Curtis JP, Go AS, Greenlee RT, Magid DJ, Normand SL, Masoudi FA. Association of single- vs dual-chamber ICDs with mortality, readmissions, and complications among patients receiving an ICD for primary prevention. JAMA. 2013 May 15;309(19):2025-34. PMID:23677314

Pfeiffer RM, Park Y, Kreimer AR, Lacey JV Jr, Pee D, Greenlee RT, Buys SS, Hollenbeck A, Rosner B, Gail MH, Hartge P. Risk prediction for breast, endometrial, and ovarian cancer in white women aged 50 y or older: derivation and validation from population-based cohort studies. PLoS Med. 2013;10(7):e1001492. Epub 2013 Jul 30. PMID:23935463

Rowhani-Rahbar A, Fireman B, Lewis E, Nordin J, Naleway A, Jacobsen SJ, Jackson LA, Tse A, Belongia EA, Hambidge SJ, Weintraub E, Baxter R, Klein NP. Effect of age on the risk of Fever and seizures following immunization with measles-containing vaccines in children. JAMA Pediatr. 2013 Dec 1;167(12):1111-7. PMID:24126936

Schonfeld SJ, Hartge P, Pfeiffer RM, Freedman DM, Greenlee RT, Linet MS, Park Y, Schairer C, Visvanathan K, Lacey JV Jr. An aggregated analysis of hormonal factors and endometrial cancer risk by parity. Cancer. 2013 Apr 1;119(7):1393-401. Epub 2012 Dec 20. PMID:23280123

Sundaram ME, McClure DL, VanWormer JJ, Friedrich TC, Meece JK, Belongia EA. Influenza vaccination is not associated with detection of noninfluenza respiratory viruses in seasonal studies of influenza vaccine effectiveness. Clin Infect Dis. 2013 Sep;57(6):789-93. PMID:23748138

Sundaram ME, Talbot HK, Zhu Y, Griffin MR, Spencer S, Shay DK, Coleman LA. Vitamin D is not associated with serologic response to influenza vaccine in adults over 50 years old. Vaccine. 2013 Apr 12;31(16):2057-61. Epub 2013 Feb 28. PMID: 23453766

Tseng HF, Sy LS, Liu IL, Qian L, Marcy SM, Weintraub E, Yih K, Baxter R, Glanz JM, Donahue J, Naleway A, Nordin J, Jacobsen SJ. Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children. Vaccine. 2013 May 24;31(22):2578-83. Epub 2013 Apr 8. PMID: 23579258

VanWormer JJ, Acharya A, Greenlee RT, Nieto FJ. Oral hygiene and cardiometabolic disease risk in the survey of the health of Wisconsin. 2013 Aug. Community Dent Oral Epidemiol; 14(4):374-84. PMID: 23106415

Xu S, Hambidge SJ, McClure DL, Daley MF, Glanz JM. A scan statistic for identifying optimal risk windows in vaccine safety studies using self-controlled case series design. Stat Med. 2013 Aug 30;32(19):3290-9. Epub 2013 Jan 10. PMID:23303643

Recent Selected Publications

Fri, 22 May 2015 14:41:33 GMT

Kieke AL, Kieke BA, Kopitzke SL, McClure DL, Belongia EA, VanWormer JJ, Greenlee RT. Validation of Health Event Capture in the Marshfield Epidemiologic Study Area. Clin Med Res. 2014 Dec; [Epub ahead of print]. PMID: 25487238

McLean (Nguyen) HQ, Thompson MG, Sundaram ME, Kieke BA, Gaglani M, Murthy K, Piedra PA, Zimmerman R, Nowalk M, Raviotta JM, Jackson ML, Jackson L, Ohmit SE, Petrie JG, Monto A, Meece JK, Thaker S, Thaker S, Clippard J, Spencer SM, Fry A, Belongia EA. Influenza Vaccine Effectiveness in the United States During 2012-13: Variable Protection by Age and Virus Type. J INFECT DIS. 2014 Nov; [Epub ahead of print]. PMID: 25406334

Dugdale C, Chow BD, Yakirevich E, Kojic E, Knoll B. Prolonged pyrexia and hepatitis: Q fever. Am J Med. 2014 Oct;[Epub ahead of print]. PMID: 24929020

VanWormer JJ, Miller AW, Rezkalla SH. S2-12: Identifying Opportunities to Improve Aspirin Utilization for the Primary Prevention of Cardiovascular Disease in a Regional Healthcare System. Clin Med Res. 2014 Oct;12(1-2):Ps2-12. PMID: 25739162

Tenisha Hill, MPH

Wed, 20 May 2015 19:18:07 GMT

Epidemiologist

1000 North Oak Avenue
Marshfield, WI 54449

715.389.7548

Tenisha is an Epidemiologist and the project manager for several studies. The first is a rural obesity study that compares the effectiveness of three approaches to weight loss. She also manages a clinical trial to determine the frequency of lysosomal acid lipase deficiency in at risk populations, and a long term follow-up study to determine the persistence of antibodies following vaccination with a third dose of MMR vaccine. As the Project Manager of these studies, she develops protocols, writes the standard operating procedures, maintains regulatory documents, acts as a liaison between the study sponsors, investigators, and study staff, and performs data analyses.

Tenisha received her Masters of Public Health (MPH) from Indiana University School of Public Health in 2014. Her independent project investigated the impact of racial discrimination on weight gain among black women. As a student, she managed existing program data for the Indiana University Women’s Center of Excellence (IU CoE). This involved development of data collection tools and analysis of data.

Prior to joining the Center for Clinical Epidemiology and Population Health in February 2015, Tenisha was a health educator at the Indiana University School of Nursing. She provided tailored interactive interventions to increase both colorectal and breast cancer screening in women ages 50 to 75.

Elizabeth Vickers, MS

Wed, 20 May 2015 18:44:24 GMT

Epidemiologist

1000 North Oak Avenue
Marshfield, WI 54449

715.389.3444

As a vaccine safety epidemiologist, Elizabeth currently acts as a Project Manager for several studies related to vaccines and respiratory illnesses. These include a phase II clinical trial to evaluate the safety and performance of an experimental vaccine in the elderly, and a phase IV clinical trial evaluating the performance of an influenza vaccine in children. In addition, Elizabeth is the project manager for studies related to the Vaccine Safety Datalink (VSD), a collaborative effort led by the CDC to examine safety of vaccines administered across the United States. Through her duties as project manager, Elizabeth aids in development of study specific documents, manages regulatory documents, ensures compliance with FDA GCP guidelines where applicable, and serves as a first point of contact for study sponsors.

Elizabeth attended the University of Michigan School of Public health and earned her Master of Public Health (MPH) specializing in Hospital and Molecular Epidemiology in 2014. During her time at the University, Elizabeth was involved in the HIVE study, a CDC funded project to evaluate influenza vaccine effectiveness in households with children. Her capstone project focused on seasonality, severity, and co-infection of respiratory viruses in this cohort.

Brian Chow

Wed, 20 May 2015 18:39:52 GMT

Researcher

1000 North Oak Avenue
Marshfield, WI 54449

715.387.9324

Dr. Chow is a Physician-Scientist interested in the prevention of fungal and viral infections, understanding what may predispose children to severe infections, and understanding the role of microbes in chronic illness. This includes clinical studies involving children and adults to evaluate vaccines, prophylactic medications, and therapeutics, as well as epidemiologic studies in health care settings.

Prior to joining Marshfield Clinic Research Foundation, Dr. Chow was an Adult/Pediatric Infectious Disease Fellow at Brown University, where he designed and ran a trial investigating fungal colonization in the Neonatal Intensive Care Unit. Dr. Chow also worked to measure improvement in HIV testing in pregnant women, with a goal of preventing mother-to-child transmission of HIV.

SELECTED PUBLICATIONS

Chow BD, Huang YT, Esper FP. Evidence of Human Bocavirus circulating in children and adults, Cleveland, Ohio. J Clin Virol. 2008 Nov;43(3):302-6. PMID: 18805051

Chow BDW, Ou Z, Esper FP. Newly recognized bocaviruses (HBoV, HBoV2) in children and adults with gastrointestinal illness in the United States. J Clin Virol. 2010 Feb;47(2):143-7. PMID: 20036617

Chow BDW, Reardon JR, Perry EO, Laforce-Nesbitt SS, Tucker R, Bliss JM. Expressed breast milk as a predictor of neonatal yeast colonization in an intensive care setting. J Ped Infect Dis 3:213-220 (2014)

Dugdale C, Chow B, Yakirevich E, Kojic E, Knoll B. Prolonged pyrexia and hepatitis: Q fever. Am J Med 2014 Jun 11. PMID: 24929020

Chow BD, Linden JR, Bliss JM. Candida parapsilosis and the Neonate: Epidemiology, Virulence and Host Defense in a Unique Patient Setting. Expert Rev Anti Infect Ther. 2012 Aug;10(8):935-46. PMID: 23030332/